Related Experiment Video
Updated: Feb 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
[Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]
1Department of Urology, Peking University First Hospital; Institute of Urology, Peking University, Beijing 100034, China.
Objective:
To determine the mechanism of sunitinib-induced autophagy in renal cell carcinoma cells.
Methods:
MTS assay was applied to detect the cell viability alteration under the treatment of sunitinib (2, 8 μmol/L). The sunitinib-induced autophagy as well as cell apoptosis was measured and compared after knocking down autophagy-related protein Beclin1 and microtubule associated protein 1 light chain 3 fusion protein (LC3) by RNA interference. The transmission electron microscope was used to observe the formation of autophagosomes in ACHN cells. The fluorescence microscope was used to monitor distribution and aggregation of endogenous LC3-II. The expressions of protein such as LC3-II, the autophagic regulation molecules protein kinase B/ mammalian target of rapamycin (Akt/mTOR) and the symbol of apoptosis poly ADP-ribose polymerase (PARP) were capable to be detected by immunoblotting assay.
Results:
Sunitinib was able to significantly trigger cell viability loss in the renal carcinoma cell ACHN, which was both in a concentration-dependent and time-dependent manner (P<0.05). After reducing the autophagy by knocking down Beclin1 and LC3, the number of cleavage of PARP was increased remarkably, whereas there was nearly not any cleavage in the mock group. By the transmission electron microscope, there were more autophagic vacuoles in ACHN cells after being administrated with sunitininb compared with the control. And the nuclear-to-cytosol translocation as well as aggregation of LC3-II was presented after sunitinib treatment by the fluorescence microscope, which was the proof of the enhanced autophagy. According to the immunoblotting, sunitinib was able to increase the accumulation of LC3-II . At the same time, the result of sunitinib combined with chloroquine, a drug which blocked the fusion of autophagosomes and lysosomes, demonstrated that the increasing amount of LC3-II was due to the enhanced autophagy flux by sunitinib treatment in ACHN cells. However, phosphorylation of Akt as well as mTOR was decreased at the same time. The rapamycin (mTOR inhibitor) or knocking down Akt subunits could change the sunitinib-induced LC3 -II accumulation, whereas overexpression of Akt subunits decreased the autophagic flux, indicating that Akt/mTOR was the target of sunitinib in autophagy.
Conclusion:
Sunitinib induced autophagy via suppressing Akt/mTOR pathway, and the autophagy was involved in apopotosis.
Insights
Sunitinib triggers autophagy in renal cell carcinoma by inhibiting the Akt/mTOR pathway. This autophagy plays a role in cancer cell apoptosis, offering insights into targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Renal cell carcinoma (RCC) is a significant health concern.
- Sunitinib is a targeted therapy used in RCC treatment.
- The precise mechanism of sunitinib's action, particularly its effect on cellular processes like autophagy, requires elucidation.
Purpose of the Study:
- To investigate the mechanism by which sunitinib induces autophagy in renal cell carcinoma cells.
- To determine the role of autophagy in sunitinib-induced apoptosis.
- To identify the specific molecular pathways targeted by sunitinib in this context.
Main Methods:
- Cell viability was assessed using MTS assays.
- Autophagy and apoptosis were measured after knocking down Beclin1 and LC3 using RNA interference.
- Transmission electron microscopy and fluorescence microscopy were used to observe autophagosome formation and LC3-II dynamics.
- Protein expression levels of LC3-II, Akt/mTOR, and PARP were analyzed via immunoblotting.
Main Results:
- Sunitinib significantly reduced ACHN cell viability in a dose- and time-dependent manner.
- Knocking down autophagy-related proteins increased apoptosis, indicated by PARP cleavage.
- Sunitinib treatment led to increased autophagic vacuoles and LC3-II accumulation, confirming enhanced autophagy.
- Inhibition of the Akt/mTOR pathway was observed, suggesting it as a key target for sunitinib-induced autophagy.
Conclusions:
- Sunitinib induces autophagy in renal cell carcinoma cells by suppressing the Akt/mTOR signaling pathway.
- The induced autophagy is implicated in the apoptotic process of cancer cells.
- Understanding this mechanism may inform the development of more effective RCC treatments.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
09:51Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...